Drug Search Results
More Filters [+]

GSK-6097608

Alternative Names: gsk-6097608, gsk 6097608, gsk6097608
Latest Update: 2024-06-26
Latest Update Note: Clinical Trial Update

Product Description

A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor CD96 (Tactile; T cell activation increased late expression), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD96 monoclonal antibody GSK6097608 targets, binds to and inhibits CD96 expressed primarily on T-cells and natural killer (NK) cells, thereby preventing its downstream signaling pathways. This may abrogate CD96-mediated inhibition of T-cell and NK cell effector function and may restore immune function and anti-tumor immune responses through the activation of T-cells and NKs. This may kill and inhibit growth of tumor cells. CD96, a type I transmembrane glycoprotein of the immunoglobulin superfamily and immunological checkpoint for CD8+ T-cells and NK cells, negatively regulates T-cell and NK cell activation and is overexpressed in a variety of cancer settings. (Sourced from: https://www.mycancergenome.org/content/drugs/gsk6097608/)

Mechanisms of Action: CD98 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-6097608

Countries in Clinic: Argentina, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Korea, Netherlands, Norway, Poland, Portugal, Romania, South Africa, Spain, Sweden, Taiwan, Thailand, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 7

Highest Development Phases

Phase 2: Head and Neck Cancer|Non-Small-Cell Lung Cancer

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

213824

P2

Recruiting

Non-Small-Cell Lung Cancer

2028-05-04

jRCT2051220100

P2

Recruiting

Non-Small-Cell Lung Cancer

2025-12-31

219885

P2

Recruiting

Head and Neck Cancer

2025-12-24

jRCT2031230371

P2

Not yet recruiting

Head and Neck Cancer

2025-11-12

Recent News Events